Anti-EGFR antibodies may get benefit as first-line treatment in metastatic right-sided colon cancer

被引：0
|
作者：
Elbaiomy, M. [1 ]
Elsayed, A. [2 ]
Akl, T. [1 ]
机构：
[1] Mansoura Univ, Oncol Ctr, Mansoura, Egypt
[2] Fac Med, Mansoura, Egypt
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.04.272
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-182
引用
收藏
页码：S314 / S315
页数：2
相关论文
共 50 条
  • [31] Monoclonal Antibodies for First-Line Treatment of Metastatic Colorectal Cancer
    Liao, Pei-Fei
    Wu, Ta-Wei
    Peng, Tzu-Rong
    AMERICAN JOURNAL OF THERAPEUTICS, 2024, 31 (03) : e286 - e297
  • [32] Anti-EGFR monoclonal antibodies in lung cancer treatment
    Schiller, Joan H.
    LANCET ONCOLOGY, 2015, 16 (07): : 738 - 739
  • [33] Real-life experience with chemotherapy plus biologics in first-line treatment of right-sided, RAS wild-type, metastatic colon cancer: A multicenter Onco-Colon Turkey study
    Arslan, C.
    Kefeli, U.
    Yildirim, E.
    Isikdogan, A.
    Karadurmus, N.
    Karabulut, B.
    Cicin, I.
    Cubukcu, E.
    Bilir, C.
    Ozcelik, M.
    Cil, T.
    Celik, S.
    Bozkurt, O.
    Harputluoglu, H.
    Oven, B.
    Geredeli, C.
    Tural, D.
    Sakin, A.
    Cevik, D.
    Gumus, M.
    Yalcin, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S174 - S174
  • [34] The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference
    Roberto, Michela
    Marchetti, Paolo
    Arrivi, Giulia
    Di Pietro, Francesca Romana
    Cascinu, Stefano
    Gelsomino, Fabio
    Caputo, Francesco
    Cerma, Krisida
    Ghidini, Michele
    Ratti, Margherita
    Pizzo, Claudio
    Ficorella, Corrado
    Parisi, Alessandro
    Cortellini, Alessio
    Urbano, Federica
    Calandrella, Maria Letizia
    Botticelli, Andrea
    Dell'Aquila, Emanuela
    Minelli, Alessandro
    Fulgenzi, Claudia
    Montori, Andrea
    Pilozzi, Emanuela
    Mazzuca, Federica
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2020, 35 (08) : 1513 - 1527
  • [35] The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference
    Michela Roberto
    Paolo Marchetti
    Giulia Arrivi
    Francesca Romana Di Pietro
    Stefano Cascinu
    Fabio Gelsomino
    Francesco Caputo
    Krisida Cerma
    Michele Ghidini
    Margherita Ratti
    Claudio Pizzo
    Corrado Ficorella
    Alessandro Parisi
    Alessio Cortellini
    Federica Urbano
    Maria Letizia Calandrella
    Andrea Botticelli
    Emanuela Dell’Aquila
    Alessandro Minelli
    Claudia Fulgenzi
    Andrea Montori
    Emanuela Pilozzi
    Federica Mazzuca
    International Journal of Colorectal Disease, 2020, 35 : 1513 - 1527
  • [36] First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis
    Isikdogan, A.
    Turk, H.
    Bilir, C.
    Sendur, M.
    Karabulut, B.
    Artac, M.
    Cicin, I.
    Geredeli, C.
    Alacacioglu, A.
    Kefeli, U.
    Harputluoglu, H.
    Bozkurt, O.
    Cubukcu, E.
    Tural, D.
    Sakin, A.
    Cil, T.
    Dane, F.
    Cevik, D.
    Arslan, C.
    Karadurmus, N.
    Gumus, M.
    Yalcin, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S281 - S281
  • [37] Impact of delayed addition of anti-EGFR monoclonal antibodies on the outcome of first-line therapy in metastatic colorectal cancer patients: A retrospective registry-based analysis
    Buchler, T.
    Fiala, O.
    Veskrnova, V.
    Chloupkova, R.
    Poprach, A.
    Kiss, I.
    Kopeckova, K.
    Dusek, L.
    Slavicek, L.
    Kohoutek, M.
    Finek, J.
    Svoboda, M.
    Dvorak, J.
    Petruzelka, L. B.
    Melichar, B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [38] Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis
    Ondrej Fiala
    Veronika Veskrnova
    Renata Chloupkova
    Alexandr Poprach
    Igor Kiss
    Katerina Kopeckova
    Ladislav Dusek
    Lubomir Slavicek
    Milan Kohoutek
    Jindrich Finek
    Marek Svoboda
    Lubos Petruzelka
    Ludmila Boubliková
    Josef Dvorak
    Bohuslav Melichar
    Tomas Buchler
    Targeted Oncology, 2018, 13 : 735 - 743
  • [39] Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis
    Fiala, Ondrej
    Veskrnova, Veronika
    Chloupkova, Renata
    Poprach, Alexandr
    Kiss, Igor
    Kopeckova, Katerina
    Dusek, Ladislav
    Slavicek, Lubomir
    Kohoutek, Milan
    Finek, Jindrich
    Svoboda, Marek
    Petruzelka, Lubos
    Boublikova, Ludmila
    Dvorak, Josef
    Melichar, Bohuslav
    Buchler, Tomas
    TARGETED ONCOLOGY, 2018, 13 (06) : 735 - 743
  • [40] Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer
    Hironori Fujii
    Hirotoshi Iihara
    Akio Suzuki
    Ryo Kobayashi
    Nobuhisa Matsuhashi
    Takao Takahashi
    Kazuhiro Yoshida
    Yoshinori Itoh
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 1209 - 1215
12345